Literature DB >> 29656942

Evolving Industry Partnerships and Investments in Cell and Gene Therapies.

Devyn M Smith1, Emily J Culme-Seymour2, Chris Mason3.   

Abstract

Cell and gene therapies hold the promise of providing significant and durable health gains to patients in many disease states and have recently elicited significant investor and partner interest. We cover the current state of industry partnerships and investments, highlight what makes a partnership advantageous, and discuss implications for stem cell therapies.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2018        PMID： 29656942     DOI： 10.1016/j.stem.2018.03.004

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  5 in total

1.  Genome Editing for Rare Diseases.

Authors:  Arun Pradhan; Tanya V Kalin; Vladimir V Kalinichenko
Journal:  Curr Stem Cell Rep       Date:  2020-07-07

Review 2.  Parallels between the Developing Vascular and Neural Systems: Signaling Pathways and Future Perspectives for Regenerative Medicine.

Authors:  Idoia Elorza Ridaura; Stefano Sorrentino; Lorenzo Moroni
Journal:  Adv Sci (Weinh)       Date:  2021-10-24       Impact factor: 16.806

Review 3.  Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases.

Authors:  Panayiota Papasavva; Marina Kleanthous; Carsten W Lederer
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

Review 4.  The impact of COVID-19 on the cell and gene therapies industry: disruptions, opportunities, and future prospects.

Authors:  Tingting Qiu; Yitong Wang; Shuyao Liang; Ru Han; Mondher Toumi
Journal:  Drug Discov Today       Date:  2021-04-20       Impact factor: 7.851

Review 5.  Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers.

Authors:  Tingting Qiu; Shuyao Liang; Yitong Wang; Claude Dussart; Borislav Borissov; Mondher Toumi
Journal:  Front Public Health       Date:  2021-11-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.